The blue-chip Swiss Market Index bounced back to positive territory on Friday, closing 0.79% higher, as investors assessed the latest corporate releases, economy-related data prints and geopolitical happenings.
Switzerland took note of the additional US tariff of up to 12.5% on its imports but rejected allegations related to a forced-labor investigation, the Swiss Federal Department of Economic Affairs, Education and Research said in a social media post on X.
"[Overnight] the Trump administration finalized the details of the new Section 301 tariffs covering some 60 of the US' trading partners. Largely in line with what was signaled when the investigations into alleged forced labour practices in supply chains concluded last month, most of the largest trading partners including the EU, UK, Canada and Mexico will face a tariff of 10%, while others including Japan, South Korea and Australia will face a 12.5% levy," according to Deutsche Bank Research. "As a reminder, these duties arrive as today sees the expiry of the temporary 10% Section 122 tariffs, which themselves were announced after the Supreme Court in February struck down tariffs introduced under the International Economic Emergency Powers Act."
Over to corporates, SGS (SGSN.SW) shares shed 2.67% at closing as it reported a year-over-year decline in first-half attributable profit to 309 million francs from 314 million francs. Sales, on the other hand, grew 7.6% over the period to 3.68 billion francs. The Swiss testing and certification company also announced a series of acquisitions, including food risk intelligence platform Agroknow in Greece, high- and low-voltage electrical systems company TechCorp Services in Australia and three companies in the US.
"The ~60bps sequential acceleration in [organic sales growth] in Q2 despite the Middle East disruption is the key positive with [Natural Resources] and [Health & Nutrition] well ahead of consensus. [Adjusted operating income] margin in line with consensus, though we note materially higher than expected non-recurring costs vs. consensus/RBCe in the period. Strong underlying FCF growth (ex HQ disposal) driven by a CHF24m YoY drop in the working capital outflow and the FY26 outlook has been maintained," RBC Capital Markets said in a quick take note.
Meanwhile, Roche (RO.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the approval of its Susvimo injection to treat neovascular age-related macular degeneration. The pharmaceutical giant's stock gained 1.29%.
Beyond Switzerland and in other news, the seasonally adjusted S&P Global Flash Eurozone Composite PMI Output Index rose to a five-month high of 51.9 in July from 50 in the previous month, reflecting a renewed increase in services business activity and a faster expansion in manufacturing output.